Diagnostic and Prognostic Performance of Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: The Clinical Application of Quantitative NextGen Mass Spectrometry

Diagnostic and Prognostic Performance of Metabolic Signatures in Pancreatic Ductal Adenocarcinoma: The Clinical Application of Quantitative NextGen Mass Spectrometry

With 64,050 new diagnoses and 50,550 deaths in the US in 2023, pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of all human malignancies. Early detection and improved prognostication remain critical unmet needs. We applied next-generation metabolomics, using quantitative tandem mass...

Full description

Bibliographic Details
Main Authors: Paulo D’Amora, Ismael D. C. G. Silva, Steven S. Evans, Adam J. Nagourney, Katharine A. Kirby, Brett Herrmann, Daniela Cavalheiro, Federico R. Francisco, Paula J. Bernard, Robert A. Nagourney
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Metabolites
Subjects:
pancreatic cancer
NextGen metabolomics
metabolic profiling
biomarker
early detection
survival analysis
Online Access:https://www.mdpi.com/2218-1989/14/3/148

Internet

https://www.mdpi.com/2218-1989/14/3/148

Similar Items